MorphoSys Announces New Management Appointments
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces New Management Appointments
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it
has strengthened its management in two positions. Charlotte Lohmann joins the
Company as General Counsel, and Martin Clark as Head of Central Purchasing &
Logistics.
Charlotte Lohmann joins MorphoSys after eleven years at Wilex AG where she was
most recently Senior Vice President Legal Affairs & Human Resources. Prior to
her position at Wilex, she practiced as a lawyer at the law firm KPMG Treuhand &
Goerdeler GmbH in Munich. She started her career in the tax and law department
of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG in the Munich
office. Mrs. Lohmann received her degree in law from the University of Munich
and is a licensed attorney.
Martin Clark joins MorphoSys from Sandoz Biopharmaceuticalswhere he managed the
delivery of projects via third party contract research organizations as Head of
Clinical Operations and Third Party Management. He has over 30 years experience
in the pharmaceutical industry filling both scientific and management positions
with Basilea, Serono, Merck-Serono, Novartis and Pfizer.
"We are very pleased to welcome outstanding individuals for two important
positions within the MorphoSys Group," explained Dr. Simon Moroney, Chief
Executive Officer of MorphoSys AG. "These additions will further strengthen and
complement our existing management team, and will help us to continue to build
MorphoSys as a leading biopharmaceutical company."
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
Company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), Ylanthia(®), CysDisplay(®),
RapMAT(®) and arYla(®) are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1615757/515147.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1615757]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.05.2012 - 01:30 Uhr
Sprache: Deutsch
News-ID 1118965
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 104 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces New Management Appointments
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
